Metformin potentiates rapamycin and cisplatin in gastric cancer in mice. - Wikidata - awgldk - TriplyDB

Metformin potentiates rapamycin and cisplatin in gastric cancer in mice.

Metformin potentiates rapamycin and cisplatin in gastric cancer in mice.

http://www.wikidata.org/entity/Q35828675

about

From rapalogs to anti-aging formula.PKM2 regulates neural invasion of and predicts poor prognosis for human hilar cholangiocarcinoma.Hippo transducer TAZ promotes epithelial mesenchymal transition and supports pancreatic cancer progression Metformin reduces gastric cancer risk in patients with type 2 diabetes mellitus.Metformin use and cervical cancer risk in female patients with type 2 diabetes Metformin and cancer: Quo vadis et cui bono?Metformin potentiates anti-tumor effect of resveratrol on pancreatic cancer by down-regulation of VEGF-B signaling pathway.Study protocol of a phase IB/II clinical trial of metformin and chloroquine in patients with IDH1-mutated or IDH2-mutated solid tumours Effects of Metformin and a Mammalian Target of Rapamycin (mTOR) ATP-Competitive Inhibitor on Targeted Metabolomics in Pancreatic Cancer Cell Line.The expanding role of metformin in cancer: an update on antitumor mechanisms and clinical development.The predictive potential and oncogenic effects of HOXC8 expression on osteosarcoma.Combinational strategies of metformin and chemotherapy in cancers.Role of AMPK signaling in mediating the anticancer effects of silibinin in esophageal squamous cell carcinoma.SPARCL1 is a novel predictor of tumor recurrence and survival in hilar cholangiocarcinoma.Celastrol induces cell cycle arrest by MicroRNA-21-mTOR-mediated inhibition p27 protein degradation in gastric cancer.Redox-dependent modulation of metformin contributes to enhanced sensitivity of esophageal squamous cell carcinoma to cisplatin.Metformin use and its effect on gastric cancer in patients with type 2 diabetes: A systematic review of observational studies.Metformin enhances the chemosensitivity of hepatocarcinoma cells to cisplatin through AMPK pathway.Metformin and blood cancers Metformin inhibits ovarian cancer growth and migration in vitro and in vivo by enhancing cisplatin cytotoxicity

P2860

Q33829205-C18B9B5E-07F4-4928-8E1C-624C4C0984FC Q36292690-CB86A276-1C20-47DC-A37F-EAFAC120A4D4 Q36546520-B2095BD6-BF9D-4891-8F15-24004BF45064 Q37274957-0DA6D911-D4B7-47DC-A613-7CA2F5D94D59 Q37644891-03FB9690-7D70-4264-9E23-0A1C54D3CB06 Q37688014-801156DA-6925-4824-BA2D-4CE44A5DB9CF Q37708932-3934F6DA-736B-4E69-A051-13FEF1803911 Q38375735-24BBDB2D-2214-4242-BC55-196020B41D4D Q38715697-E55EE5AF-4054-43EE-8295-401B00077DE6 Q38728567-074EB11E-C265-4B3F-9E17-67F0C866EB1C Q38744613-74D161C0-934E-4C08-AB9D-CBCBB05A6056 Q38818730-B157A5CE-5D9F-4503-9115-4837837A5890 Q38819571-DE325810-71E9-494E-8781-25F905B9FAED Q38826019-21ACA995-164A-4EDF-83EB-CC8011FC154A Q42061952-EDBEC28A-BF51-4C11-A26D-1C0A145054C5 Q42365321-97B0398A-70B3-42B2-8553-AF69A1A70273 Q49183232-6BDBF644-61FB-404E-83C4-9CC464E87BC4 Q49658205-D7EA17F7-5947-466A-9444-C85DCE7818EE Q58699189-72A5282D-F408-4338-9C31-5F6BE25EDD44 Q58733981-F00605A4-6C04-4F6A-B0ED-484A1343842A

P2860

Metformin potentiates rapamycin and cisplatin in gastric cancer in mice.

http://www.wikidata.org/entity/Q35828675

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Metformin potentiates rapamycin and cisplatin in gastric cancer in mice.

@ast

Metformin potentiates rapamycin and cisplatin in gastric cancer in mice.

@en

type

label

Metformin potentiates rapamycin and cisplatin in gastric cancer in mice.

@ast

Metformin potentiates rapamycin and cisplatin in gastric cancer in mice.

@en

prefLabel

Metformin potentiates rapamycin and cisplatin in gastric cancer in mice.

@ast

Metformin potentiates rapamycin and cisplatin in gastric cancer in mice.

@en

P1433

Q35828675-AF93177D-2BCB-42C7-B2CC-A6C3BDC6E8B8

P1476

Q35828675-26511931-1D24-4C1A-9876-4FFCDE414FDE

P2093

Q35828675-17FCB29F-DA58-4AF3-9685-AE9E627083E4

Q35828675-1F3A249E-D95B-45FC-BCBC-29CAD71634A5

Q35828675-2FE900C5-7508-438F-A1D6-44CE996160A2

Q35828675-4235775A-EC3B-4DEB-ADEE-9B52AE49D535

Q35828675-4A453A3D-0EFA-4302-AB6C-87BDF95EBF11

Q35828675-7D684EEC-0DD0-464E-90A8-762D1502523C

Q35828675-9413DB91-F760-45CA-9C40-4184983626C8

Q35828675-AD71619A-C3E9-45C2-A870-297DA3526ECD

Q35828675-B123342A-D9A1-41B5-AB36-D6047AE1F4EF

Q35828675-F36727CB-A978-43EB-BA32-32925932AC74

P2860

Q35828675-017EB223-B199-4A52-BBA7-C7220FD52158

Q35828675-054BC540-031C-408F-807A-87A9C0424036

Q35828675-056989B8-DA20-49FE-9F3F-15902A65516B

Q35828675-0692F700-BAF0-4F30-810A-421791078973

Q35828675-1463747C-1FC3-4B77-8C48-4CE57590C9C6

Q35828675-209B256B-6FF2-4BB4-BC19-BDE65E744491

Q35828675-21372344-0B4A-47D6-B8EC-A3EAEE750DD3

Q35828675-213F74BC-8A0B-44CF-A874-4BA17C845F2A

Q35828675-31442ED5-C3CC-4D52-BCC6-95B295610925

Q35828675-3D267BB1-A1AF-4474-AFDD-D145386CBBAD

P304

Q35828675-8874514E-FEDD-4FA1-B4EB-05CC6CE49BD3

P31

Q35828675-BFE38177-6F23-4C86-BCAA-2D4FA8B262F8

P356

Q35828675-3A1EC35A-0F61-46D2-A7E2-E35133D80423

P407

Q35828675-CB9EE776-AB03-4397-BB6C-9E611515DFC9

P433

Q35828675-8D95E263-4BA3-46E7-8F5D-82E81E37E16E

P478

Q35828675-0CD6BA90-B1CE-4C5C-A354-7F7DCA7A7279

P577

Q35828675-39CB8860-C819-4673-A5D8-BF95E5E25B9E

P5875

Q35828675-5C5FB486-73E4-417D-8F78-A2F3BA59050D

P698

Q35828675-12D62F14-BC38-4FCA-BCD8-864E2AA8E665

P921

Q35828675-2923CD21-69CE-49F5-B57A-4DAFA50F3534

P932

Q35828675-3BE77106-0CCB-4DC5-8342-F38FBC0E792C

P356

ONCOTARGET.3327

P1433

P1476

Metformin potentiates rapamycin and cisplatin in gastric cancer in mice.

@en

P2093

Guanzhen Yu

http://www.w3.org/2001/XMLSchema#string

Jiejun Wang

http://www.w3.org/2001/XMLSchema#string

Keping Xie

http://www.w3.org/2001/XMLSchema#string

Suyun Huang

http://www.w3.org/2001/XMLSchema#string

Tian Xia

http://www.w3.org/2001/XMLSchema#string

Wenzheng Fang

http://www.w3.org/2001/XMLSchema#string

Xiaodong Jiao

http://www.w3.org/2001/XMLSchema#string

Ying Chen

http://www.w3.org/2001/XMLSchema#string

Yunshu Gao

http://www.w3.org/2001/XMLSchema#string

Zhaosheng Li

http://www.w3.org/2001/XMLSchema#string

P2860

AMP-activated protein kinase: a target for drugs both ancient and modern

Metformin: a therapeutic opportunity in breast cancer.

Type 2 diabetes increases and metformin reduces total, colorectal, liver and pancreatic cancer incidences in Taiwanese: a representative population prospective cohort study of 800,000 individuals.

Long-term metformin use is associated with decreased risk of breast cancer.

The influence of transforming growth factor-α, cyclooxygenase-2, matrix metalloproteinase (MMP)-7, MMP-9 and CXCR4 proteins involved in epithelial-mesenchymal transition on overall survival of patients with gastric cancer.

Stat3 and MMP7 contribute to pancreatic ductal adenocarcinoma initiation and progression.

Metformin suppresses ovarian cancer growth and metastasis with enhancement of cisplatin cytotoxicity in vivo.

Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer.

Braveheart, a long noncoding RNA required for cardiovascular lineage commitment

PTEN and the PI3-kinase pathway in cancer

P304

12748-12762

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.18632/ONCOTARGET.3327

http://www.w3.org/2001/XMLSchema#string

P407

P433

14

http://www.w3.org/2001/XMLSchema#string

P478

6

http://www.w3.org/2001/XMLSchema#string

P577

2015-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

275355577

http://www.w3.org/2001/XMLSchema#string

P698

25909163

http://www.w3.org/2001/XMLSchema#string

P921

P932

4494971

http://www.w3.org/2001/XMLSchema#string